一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Molecular Cancer Therapeutics >>article
Molecular Cancer Therapeutics

Molecular Cancer Therapeutics

IF: 5.3
Download PDF

Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma

Published:24 July 2019 DOI: 10.1158/1535-7163.mct-18-1181
Kexin Xu,?Geng Sun,?Min Li,?Hongling Chen,?Zuhao Zhang,?Xixi Qian,?Ping Li,?Lin Xu,?Wenbin Huang,?Xuerong Wang

Abstract

Sulfonylurea receptor 1 (SUR1) is the regulatory subunit of ATP-sensitive potassium channels (KATP channels) and the receptor of antidiabetic drugs, such as glibenclamide, which induce insulin secretion in pancreatic β cells. However, the expression and role of SUR1 in cancer are unknown. In this study, we found that SUR1 expression was elevated in human non–small cell lung carcinoma (NSCLC) tissues and cell lines. SUR1 silencing suppressed the growth of NSCLC cells, while SUR1 overexpression promoted cell growth. Targeting SUR1 with glibenclamide suppressed cell growth, cell-cycle progression, epithelial–mesenchymal transition (EMT), and cell migration. Moreover, SUR1 directly interacted with p70S6K and upregulated p70S6K phosphorylation and activity. In addition, glibenclamide inhibited p70S6K, and overexpression of p70S6K partially reversed the growth-inhibiting effect of glibenclamide. Furthermore, glibenclamide upregulated the expression of the tumor suppressor Krüppel-like factor 4 (KLF4), and silencing KLF4 partially reversed the inhibitory effect of glibenclamide on cell growth, EMT, and migration. We found that SUR1 targeted p70S6K to downregulate KLF4 expression by enhancing DNA-methyltransferase 1–mediated methylation of the KLF4 promoter. Finally, in xenograft mouse models, SUR1 expression silencing or glibenclamide treatment inhibited the growth of A549 tumors, downregulated p70S6K activity, and upregulated KLF4 expression. These findings suggested that SUR1 expression was elevated in some NSCLC tissues and functioned as a tumor enhancer. Targeting SUR1 with glibenclamide inhibited NSCLC through downregulation of p70S6K activity and subsequent upregulation of the expression of the tumor suppressor gene KLF4. SUR1 can be developed as a new target for cancer therapy and glibenclamide has potential anticancer effects.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
TRICHOSTATIN A 58880-19-6 C17H22N2O3 315 suppliers $56.00-$4500.00
TRICHOSTATIN A 58880-19-6 C17H22N2O3 315 suppliers $56.00-$4500.00
TRICHOSTATIN A 58880-19-6 C17H22N2O3 315 suppliers $56.00-$4500.00
TRICHOSTATIN A 58880-19-6 C17H22N2O3 315 suppliers $56.00-$4500.00

Similar articles

IF:9.6

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Cancer treatment reviews Jordi Remon , Lizza E.L. Hendriks ,etc Published: 1 November 2020
IF:3

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Saudi Pharmaceutical Journal Silky Bedi , Shah A. Khan ,etc Published: 1 September 2018
定日县| 广宁县| 鹤壁市| 苍南县| 宁都县| 迭部县| 唐河县| 繁峙县| 山东省| 舞阳县| 扎囊县| 洪洞县| 永新县| 瑞丽市| 东阿县| 雅江县| 加查县| 渭南市| 大荔县| 泸水县| 北流市| 临武县| 郓城县| 高邮市| 泊头市| 屯门区| 万山特区| 静海县| 鄂托克前旗| 于都县| 南丰县| 屏南县| 赞皇县| 田东县| 土默特右旗| 偏关县| 平江县| 新河县| 南召县| 田阳县| 巫山县|